What will a merger do for Tate & Lyle and Ingredion?

Shares in Tate & Lyle rocketed 45% last week after the specialist ingredients giant confirmed it was in talks with US peer Ingredion.

Ingredion offered Tate shareholders £2.7bn for a 100% buyout of the UK plc, the majority in cash at up to 615p per share. It is a 67% premium on Tate’s six-month average share price, and would bring its valuation in line with European peers.

So, what would a merger mean to the two?

Headquartered in Illinois, Ingredion generates an annual $7.2bn (£5.4bn) revenue to Tate’s roughly £2bn.

Born out of the US maize industry, Ingredion historically specialised in corn starch and high-fructose corn syrup. But towards the millennium both Ingredion and Tate began expanding their offering into additives that could change the texture of food or cut sugars out.

Tate’s 2010 divestment of its sugar business cemented this shift, bringing it into direct competition with Ingredion’s $2.4bn Texture & Healthful Solutions (T&H) division.

A combination “makes sense” for Ingredion, according to UBS analyst Priyanka Patel.

While the two compete head-to-head in segments including food texture, UBS places Tate as the world leader in sweetening and soluble fibres. Sweeteners make up just 7% of Ingredion’s T&H portfolio, but 27% of Tate’s.

Patel says the deal would help “build out” Ingredion’s T&H business, which operates downstream from its bulk ingredients division. It would also take T&H from around 33% of Ingredion sales to about 53%.

Given Tate and the T&H division share a “great deal of similarities”, the deal gives “good scope for Ingredion to deliver both cost and revenue synergies”, says Deutsche Numis analyst Damian McNeela.

The cost synergies would be about £115m, estimates Investec – worth over a quarter of Tate’s current EBITDA of £417m.

GLP-1s and HFSS

The deal would also fit a broader trend of consolidation in ingredients, as companies seek to become end-to-end reformulation partners for food brands reacting to changing regulation and GLP-1 uptake.

GLP-1s and HFSS regulation are not just an opportunity – they are also a significant threat to these highly specialist companies. Both have evolved alongside a highly processed market and are entwined in confectionery, bakery, snacks and sugary beverages.

Berenberg estimates 39% of Tate’s group revenue would be “highly negatively affected” by increased GLP-1 use, compared with 17% that would benefit from the increased demand for reformulation.

Analyst Matthew Abraham estimates Tate’s current market presence “insufficient” to make it a net beneficiary from GLP-1- related product redesign.

But a combination of the two groups’ capacity in on-trend fortificants like fibre and plant protein might change that picture.

Plus, Tate is cheap. Its shares have declined 60% over the past five years, pre-bid, with little prospect of a revival under its own steam, according to Patel. A pair of profit warnings in 2025 have helped keep the stock subdued, rounding off 10 years of trading at a discount to its European peers.

McNeela is “not surprised” a bid has been made.

The City has largely reacted positively to the bid – but hurdles remain. Investors canvassed by UBS said their main concern was around the combined entity’s debt pile after funding such a large cash deal.

And the price isn’t set in stone. Tate says multiple previous bids were made, but not announced. Even a small increase in price would see post-deal debt soar – and counter private equity offers “cannot be ruled out”, says McNeela.

If the two giants agree to a deal, the final hurdle will be antitrust scrutiny. Starches would be the greatest area of overlap: if the smaller of the two US starch businesses was to be divested, it would be a $400m blow to sales. There is a further $50m of overlap in stevia, UBS estimates, among others.

Ingredion has until 11 June to make a firm offer.